In addition, we evaluated SAA levels in 138 serum samples derived from patients with NNL diseases of the cervix, CIN (precursor of cancer), and uterine cervical carcinomas and found that the circulating levels of SAA gradually increased with the carcinogenesis and progression of cervical cancer. The gene discussed is SAA2; the disease is cervical cancer.